SCYNEXIS Inc (SCYX) company profile
Close on Nov 17, 2026Market cap $28.36MP/E –Yield –
About Scynexis
Pharmaceutical Preparations, SIC 2834
SCYNEXIS, Inc. is a biotechnology company that develops treatments for severe diseases, focusing on drug-resistant and difficult-to-treat fungal infections. The company creates therapies using its proprietary platform of triterpenoid antifungal agents known as fungerps. Its lead commercialized product is ibrexafungerp, marketed as BREXAFEMME for vaginal yeast infections and licensed to GSK. SCYNEXIS also advances clinical candidates such as SCY-247, an antifungal evaluated in oral and intravenous formulations for invasive candidiasis. Its therapies target hospitalized and immunocompromised patients treated by infectious disease specialists, oncologists, and critical care physicians at major medical centers.
The company maintains an international operational reach through licensing agreements covering regions including the United States, Greater China, and Russia. SCYNEXIS does not own or operate manufacturing, storage, or laboratory facilities, relying instead on external contract manufacturers to produce its clinical supplies and drug products. The provided text does not disclose the location of the company's corporate headquarters.
Summary of the business section of Scynexis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SCYNEXIS Inc
- Founded
- 1999
- Headquarters
- Jersey City, NJ
- Address
- 1 Evertrust Plaza, 13th Floor 07302-6548
- Phone
- (201) 884-5485
- Website
- scynexis.com
- Employees
- 18, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- SCYX
- Exchange
- Nasdaq
- IPO date
- May 2, 2014
- Shares outstanding
- 10M, Aug 1, 2026
- Public float
- $25.65M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-8 reverse, Jun 1, 2026; 1-for-10 reverse, Jul 17, 2020
- SEC CIK
- 1178253
- CUSIP
- 811292309
- ISIN
- US8112923094
- FIGI
- BBG002133YW4
- Share class FIGI
- BBG002133YY2
- LEI
- 529900XBHFGMNTU70154
- EIN
- 56-2181648
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gonzalez David Angulo | Chief Executive Officer, Director | 1,357,126 |
| Sanjay Subramanian | Chief Financial Officer | – |
| ivor Macleod | Chief Financial Officer | 398,529 |
| Scott Sukenick | Chief Legal Officer | 574,539 |
| Steven Keith Burke | Director | 5,750 |
| Guy Macdonald | Director | 12,625 |
| Armando Anido | Director | 11,750 |
| Ann Hanham | Director | 11,577 |
| Brian Philippe Tinmouth | Director | 12,125 |
| David C. Hastings | Director | 11,522 |
| Steven C. Gilman | Director | 70,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.54M | $947.17K | $854.93K | $41 | – |
| FY2024 David Angulo MD | $2.03M | $1.43M | $1.18M | $78 | – |
| FY2024 Marco Taglietti MD | $0 | $0 | $1.18M | $78 | – |
| FY2023 David Angulo MD | $1.21M | $1.49M | $781.80K | $143 | – |
| FY2023 Marco Taglietti MD | $0 | $0 | $781.80K | $143 | – |
| FY2022 | $0 | $0 | $1.10M | $26 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| David Angulo President and Chief Executive Officer | $626.04K | $283.96K | $307.31K | $312.37K | $10.50K | $1.54M | -24% |
| Ivor Macleod Chief Financial Officer | $467.48K | $99.91K | $108.13K | $173.14K | $10.50K | $859.16K | -28% |
| Scott Sukenick Chief Legal Officer | $459.96K | $99.91K | $108.13K | $172.21K | $10.50K | $833.02K | -29% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 2, 2014
- Offer price
- $10.00
- Securities offered
- 6,200,000
- Gross proceeds
- $62.00M
- Exchange
- Nasdaq
- First trading day
- May 2, 2014
- First-day close
- $9.00-10.0%
- Lock-up ends (est.)
- Oct 29, 2014
“The initial public offering price is $10.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had 18 employees, all of whom were employed on a full-time basis.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 31, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 26, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 24, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 8, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 21, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 14, 2015 | Late filing | Notification of late filing |
| Jul 23, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 2, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 19, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?